About us

Invivo Ventures is managed by Invivo Capital Partners, promoted by Albert Ferrer and Lluís Pareras, with the experience gained through the first fund Healthequity SCR. The fund has achieved a first closing of 40M €.

Invivo Ventures has a team of highly qualified professionals, with the scientific, technical and financial know-how required to analyze and make investments to provide value to the invested company. It also has a network of contacts and key strategic relationships in the health ecosystem.

Invivo Ventures FCR has been registered to the CNMV in March 2019.

It is a fund financed by the European Investment Fund (EIF), Instituto de Crédito Oficial (ICO), the Institut Català de Finances (ICF) and other private investors.

European Investment Fund (EIF)Instituto de Crédito Oficial (ICO)Institut Català de Finances (ICF)

 

 

 

 

 

 

 

INVESTMENT STRATEGY

Invivo Ventures FCR seeks projects according to the following criteria:

  • Powerful proof of concept: solid scientific package with convincing results in animal models.
  • Unique technology/ disruptive product: innovation/ science should represent a substantial improvement over current technology.
  • Roadmap and clearly defined costs.
  • Multidisciplinary and committed team.
  • Specific indications that can be complemented with line extensions.
  • Strong protection of intellectual property or the ability to generate strong entry barriers for competitors.

Initial investments will be in the range of 0.5-2M €, and could reach up to for 4M € with the achievement of pre-established milestones.

A significant amount of the funds raised will be invested in Spain and a percentage of the volume of the fund is considered for investments syndicated with other funds in European companies. 

The Fund will focus on investing in companies in early stages, mainly in the technology transfer phase. In the case of biotechnology companies, they should have a solid proof of concept in animal models and in the case of medical devices or digital health companies, they should have a prototype close to the market.

The Fund wants to diversify risks by investing in companies in different stages and different sub-sectors within the biomedical area: biotechnology, medical devices and digital health.

 

 

 

 

 

Team

Invivo Ventures is formed by professionals with the experience and know-how to add value in the creation and growth of healthcare companies:

Dr. Lluís Pareras Lluís Pareras

Partner

Degree and PhD in Medicine, specialist in Neurosurgery, and Global Executive MBA (IESE).
He founded the "Innovation and entrepreneurship program" at the Barcelona Medical Association (CoMB), where he has been coaching entrepeneurs and he has founded and directed the Healthcare Investment Forums since 2009.
He has been an entrepreneur himself in the healthcare space and raised capital from investors.
Deeply involved in the innovation ecosystem, he is a member and advisor of many healthcare innovation organizations such as Biocat (Board of Trustees), CIMTI, BarcelonaActiva Mentoring Program, Generalitat de Catalunya-CASOST and HEALTHIO among others.
Author of numerous books in the field of innovation, venture capital and healthcare, such as "Innovation and Entrepreneurship in Healthcare", published internationally. In the academic space, he has been a teacher in several business schools about healthcare innovation and venture capital.
He remains as the Director of Healthequity, SCR, a venture capital fund focused in early-stage companies in the healthcare sector, where he led the investment strategy and transaction processes of the different portfolio companies. Member of the Board of Directors of different life-sciences companies including Healthequity's investments: Versantis, n-life Therapeutics and Minoryx Therapeutics.
He has founded the managing company Invivo Capital Partners together with Albert Ferrer.

Albert Ferrer Albert Ferrer

Partner

Graduated in Business Administration and MBA from ESADE, Master CEMS (Community of European Management Schools) in Management from HEC – Hautes Études Commerciales (París) and Chartered Financial Analyst (CFA).
He has been involved in the Spanish VC industry for the past 15 years through Grupo Financiero Riva y García with a focus on high-growth, early stage, technology centered investments.
Previously, he led the finance department of an internet start-up. He also worked in the marketing department of multinational corporations.
Specialist in corporate and asset valuation, transaction structuring and execution. Experienced in different transactions: capital increases, mezzanine loans, company acquisitions, trade sales, asset sales and international transactions. He has been a member of the Board of Directors of various companies such as Wecare-u and Scytl.
He remains as  the Director of Healthequity, SCR, a venture capital fund focused in early-stage companies in the healthcare sector. He led the investment strategy and transaction processes of the different portfolio companies. He has been a member of the Board of Directors of different life-sciences companies and of Healthequity's investments: Sanifit, Peptomyc and GlyCardial Diagnostics.
He has founded the managing company Invivo Capital Partners together with Lluís Pareras.

 

Georgina Sorrosal Georgina Sorrosal

Investment analyst

Bachelor of Science in Biotechnology from the Autonomous University of Barcelona (UAB), PhD in Genetics from the University of Barcelona (UB) and Master’s Degree in Management of Business Aspects of Science and Technology from Barcelona School of Management (UPF).
More than 5 years of research in Developmental Genetics and Control of Cell Growth at the Institute for Research in Biomedicine (IRB) in Barcelona, being the author of several scientific publications in peer-reviewed journals.
3 years of experience as a Project Manager in drug development at the biotech company Advancell, S.A, and more than 2 years of experience as a Portfolio Manager and Business Development at the Knowledge Transfer and Innovation unit at Vall d'Hebron Institute of Research in Barcelona (VHIR).
She also created the working group "ASBTEC and business" through the non-profit Association of Biotechnologists of Catalonia (ASBTEC), to foster relations between scientific research and biotech companies.
She usually collaborates with different entities of the health innovation ecosystem as a start-up mentor and evaluator (COMB, EIT Health, Ship2b, Fundació Bosch i Gimpera, among others) and as a teacher in the “Project management for pharma development process” postgraduate course at University of Barcelona (UB).
Since May 2016, she has been working as Investment analyst at Healthequity, SCR, a venture capital fund focused in early-stage companies in the healthcare sector.

Laura Rodríguez Laura Rodríguez

Investment analyst

Bachelor of Science in Biotechnology from the Autonomous University of Barcelona (UAB), PhD in Biotechnology from the University of Barcelona (UB) and a Postgraduate course in Innovation Management (UAB).
5 years of experience in research in gene therapy applications in the cancer field that led to publications in peer-reviewed journals and collaborations with biotech companies. She has more than 2 years of experience as a Project Manager in the Knowledge Transfer and Innovation Unit at the Research Institute of the Vall d'Hebron Hospital (VHIR) in Barcelona.
She is an active member in the EIT Health Alumni Network, after her participation in the EIT Health Innovation & Business Creation Summer School, in 2016, co-organized by the Trinity College in Dublin and IESE business school. She usually collaborates with different entities of the health innovation ecosystem as a start-up mentor and evaluator (COMB, EIT Health, Ship2b, Imagine IF!, FIPSE and CIMTI, among others).
Since January 2018, she works as investment analyst in Healthequity SCR, a venture capital fund focused in early-stage companies in the healthcare sector.

News

 

Contact